Unknown

Dataset Information

0

SARS-CoV-2 vaccine response in ANCA associated vasculitis patients.

ABSTRACT:

SUBMITTER: Floyd L 

PROVIDER: S-EPMC8664608 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Comorbidities in ANCA-associated vasculitis.
| S-EPMC7190116 | biostudies-literature
Unknown Updates in ANCA-associated vasculitis.
| S-EPMC5058451 | biostudies-literature
Unknown Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.
| S-EPMC4587702 | biostudies-literature
Unknown Complement Inhibition in ANCA-Associated Vasculitis.
| S-EPMC9307875 | biostudies-literature
Unknown Outcome and treatment of elderly patients with ANCA-associated vasculitis.
| S-EPMC4491279 | biostudies-literature
Unknown Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients.
| S-EPMC8756656 | biostudies-literature
Unknown Long-term outcomes in elderly patients with ANCA-associated vasculitis.
| S-EPMC7671635 | biostudies-literature
Unknown PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
| S-EPMC8311572 | biostudies-literature
Unknown Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
| S-EPMC7612177 | biostudies-literature
Unknown Progress in treatment of ANCA-associated vasculitis.
| S-EPMC3446448 | biostudies-literature